Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
05/1999
05/14/1999WO1999023237A1 Transfecting peptide vector, composition containing same and applications
05/14/1999WO1999023217A1 A novel gene and uses therefor
05/14/1999WO1999023212A1 Novel streptococcal ers
05/14/1999WO1999023109A2 A method for mapping the active sites bound by enzymes that covalently modify substrate molecules
05/14/1999WO1999023108A1 Inducible phosphofructokinase and the warburg effect
05/14/1999WO1999023106A1 Caspase-14 polypeptides
05/14/1999WO1999022934A1 Prepolymer compositions comprising an antimicrobial agent
05/14/1999WO1999022763A2 Encapsulated immunomodulators useful as vaccine adjuvants
05/14/1999WO1999022744A1 Use of aliphatic polyamines for reducing oxalate
05/14/1999WO1999022741A1 Antimutagenic compositions for treatment and prevention of photodamage to skin
05/14/1999WO1999022732A1 Novel metal complexes
05/14/1999WO1999022731A1 Method and composition for treatment of sexual dysfunction
05/14/1999WO1999022729A1 The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
05/14/1999WO1999022713A1 Sustained release ophthalmic compositions containing water soluble medicaments
05/14/1999WO1999004752A3 Methods for treating skin pigmentation
05/14/1999WO1999004265A8 Cancer associated nucleic acids and polypeptides
05/14/1999WO1999001764A3 METHOD FOR DETERMINING GnRH RECEPTORS
05/14/1999WO1999001124A9 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
05/14/1999WO1998052582A9 Non-myeloablative tolerogenic treatment
05/14/1999WO1998047480A3 Membrane system for controlled tissue regeneration in cases of diseases of the peridontium
05/14/1999CA2315221A1 Method and composition for treatment of sexual dysfunction
05/14/1999CA2308385A1 Antimutagenic compositions for treatment and prevention of photodamage to skin
05/14/1999CA2308316A1 Novel metal complexes
05/14/1999CA2308112A1 Caspase-14 polypeptides
05/14/1999CA2308091A1 Inducible phosphofructokinase and the warburg effect
05/14/1999CA2307839A1 Gene involved in metabolic energy and obesity
05/14/1999CA2307805A1 A method for mapping the active sites bound by enzymes that covalently modify substrate molecules
05/14/1999CA2307541A1 Encapsulated immunomodulators useful as vaccine adjuvants
05/14/1999CA2307219A1 Prepolymer compositions comprising an antimicrobial agent
05/14/1999CA2302379A1 Sustained release ophthalmic compositions containing water soluble medicaments
05/12/1999EP0915162A2 Adenine phosphoribosyltransferase
05/12/1999EP0914825A2 Methods for preparation of 1 alpha, 24-dihydroxy vitamin D2
05/12/1999EP0914821A2 Method for diagnosis of atherosclerosis involving measurement of NADPH oxidase activity
05/12/1999EP0914614A1 CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrP?c AND PrP?sc
05/12/1999EP0914605A1 Molecular model for vla-4 inhibitors
05/12/1999EP0914460A1 Vehicle for the transport of molecular substances
05/12/1999EP0914453A1 HUMAN INTERLEUKIN-1j AND ANTAGONISTS THEREOF
05/12/1999EP0914448A1 Lipid kinase
05/12/1999EP0914422A1 Mammalian genes involved in viral infection and tumor suppression
05/12/1999EP0914330A1 Novel compounds
05/12/1999EP0914328A1 STREPTOCOCCUS PNEUMONIAE ALANYL tRNA SYNTHETASE
05/12/1999EP0914327A1 NOVEL LysS PROTEINS FROM STREPTOCOCCUS PNEUMONIAE
05/12/1999EP0914325A1 Modulators of the function of fas receptors and other proteins
05/12/1999EP0914202A1 Preservation by foam formation
05/12/1999EP0914166A1 Methods of terminal sterilization of biological products
05/12/1999EP0914163A1 Novel processes implementing selective immune down regulation (sidr)
05/12/1999EP0914158A2 Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity
05/12/1999EP0914155A1 Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
05/12/1999EP0914147A1 Atrial natriuretic peptide (anp) as an additive to peritoneal dialysis solutions
05/12/1999EP0914146A1 Morphogen treatment for chronic renal failure
05/12/1999EP0914145A1 Methods of controlling axonal growth
05/12/1999EP0914140A1 Parasitic helminth larval thiol specific antioxidant proteins, nucleic acid molecules, and uses thereof
05/12/1999EP0914138A1 Complex preparations characterised by a betain content
05/12/1999EP0914135A1 Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
05/12/1999EP0914124A1 ANTITHROMBOTIC AND ANTIATHEROGENIC PHARMACEUTICAL COMPOSITION INCLUDING A THIENOPYRIDINE DERIVATIVE AND AN HMG-CoA-REDUCTASE INHIBITOR
05/12/1999EP0914116A1 Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
05/12/1999EP0914111A2 Method for the prevention and treatment of cachexia and anorexia
05/12/1999EP0914110A1 Method of modulating microcirculation
05/12/1999EP0914108A1 Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
05/12/1999EP0914102A1 Compositions and methods for treating or preventing diseases of body passageways
05/12/1999EP0914097A2 Composition and dosage form comprising opioid antagonist
05/12/1999EP0914043A1 Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof
05/12/1999EP0914040A1 Antimicrobial composition and methods of use therefor
05/12/1999EP0883398A4 Method of inhibiting photoaging of skin
05/12/1999EP0808162B1 Use of carbazole compounds for the manufacture of a medicament for the treatment of congestive heart failure
05/12/1999EP0735888A4 Purine compositions and methods for administration
05/12/1999CN1216584A Immunity to trypanosomatids species
05/12/1999CN1216470A DHEA combination therapy
05/12/1999CN1216468A Use of dipeptidyl peptidase IV inhibitors for lowering the blood glucose level mammals
05/11/1999US5902831 Administering reduced nicotinamide-adenine dinucleotide phosphate oxidase inhibitor to treat condition resulting from endothelial hyperpermeability
05/11/1999US5902829 Administering prior to surgery a modulating mixture of l-arginine or a precursor thereof and a carrier; prevention of hypoperfusion-reperfsion injury and amelioration of hypoperfusion; substrate for nitic oxide synthetase;
05/11/1999US5902811 Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions
05/11/1999US5902809 Arglabin compounds and therapeutic uses thereof
05/11/1999US5902807 Administering alpha-2-adrenoceptor antagonist selective for alpha-2c-adrenoceptor subtype
05/11/1999US5902805 Treating of skin aging by desquamation of skin cells, comprises administering to the patient an effective amount of hydroxy-3-methylglutaryl/3-/ coenzyme reductase inhibitor selected from mevastatine, lovastatine, fluvastatine etc.
05/11/1999US5902796 Bioactive factors of aloe vera plants
05/11/1999US5902794 Camp derivatives, one is selective for site 1 of a type ii camp dependent protein kinase and the other is selective for site 2 of type i or ii camp dependent protein kinase, having a synergistic inhibitory effect on cancer cell growth
05/11/1999US5902789 Intranasally administering composition consisting of insulin, polysorbate-80, nonoxynol-9; reduced nasal irritation
05/11/1999US5902610 Formulations and methods of use of 2,2'-dithio-bis-ethane sulfonate
05/11/1999US5902567 Administering to lung by inhalation physiologically acceptable salt to hydrate secretions, concurrently administering uridine triphosphate or derivative to stimulate secretion, collecting expectorated mucus sample
05/06/1999WO1999021998A1 Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
05/06/1999WO1999021583A1 Method of inhibiting metastases of cancer cells
05/06/1999WO1999021582A2 Application of tnf antagonists as medicaments for treating septic diseases
05/06/1999WO1999021574A2 Enhancement of morphogen activity
05/06/1999WO1999021567A1 Pharmaceutical compositions for oral administration of molecular iodine
05/06/1999WO1999021565A1 Nutritional supplement for cerebral metabolic insufficiencies
05/06/1999WO1999021562A1 Treatment of female sexual dysfunction
05/06/1999WO1999021558A2 Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
05/06/1999WO1999021552A1 Use of non-immunosuppressive compounds for promoting nerve regeneration
05/06/1999WO1999021540A2 Method of reducing craving in mammals
05/06/1999WO1999021539A1 Method for treating disease-related or drug-induced dyskinesias
05/06/1999WO1999021534A1 Solid state solutions and dispersions of poorly water soluble drugs
05/06/1999WO1999021512A1 Methods and pharmaceutical compositions for the closure of retinal breaks
05/06/1999WO1999021508A1 Administration of active agents, including 5-ht receptor agonists and antagonists, to treat premature ejaculation
05/06/1999WO1999021422A1 Treatment of schizophrenia with ampakines and neuroleptics
05/06/1999WO1999012963A3 Cysteine rich receptors: trail
05/06/1999WO1999007407A9 Heparin-binding growth factor (hbgf) polypeptides
05/06/1999EP0913479A2 Adenine glycosylase
05/06/1999EP0913478A2 Histidine kinase from Streptococcus pneumoniae 0100993
05/06/1999EP0913476A2 Ornithine carbamoyl transferase sequence and uses thereof
1 ... 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 ... 1151